Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.

To gain a better understanding of the active site of cytochrome P-450 (CYP) 3A4, a three-dimensional-quantitative structure activity relationship model was constructed using the structures and K(m (apparent)) values of 38 substrates of human liver microsomal CYP3A4. This pharmacophore was built using the program Catalyst and consisted of four features: two hydrogen bond acceptors, one hydrogen bond donor, and one hydrophobic region. The pharmacophore demonstrated a fit value (r) of observed and expected K(m(apparent)) value of 0.67. The validity of the CYP3A4 substrate model was tested by twice permuting (randomizing) the activity values and substrate structures. The results of this validation procedure indicated that the original model was a significant representation of the features required of CYP3A4 substrates. The second validation method used the Catalyst model to predict the K(m(apparent)) values of a test set of structurally diverse substrates for CYP3A4 not included in the 38 molecules used to build the model. Two fitting algorithms included in this software were examined: fast fit and best fit. The fast fitting method resulted in predictions for all 12 substrates that were within 1 log unit for the residual [i.e., the difference between predicted and observed K(m(apparent))]. In contrast, the best fit algorithm poorly predicted the K(m (apparent)) values (i.e., residual >1 log unit) of 4 of 12 substrates. These poor fits with the best fit function suggest that the fast fit method within Catalyst is more representative of the observed K(m(apparent)) values for CYP3A4 substrates and enables good in silico prediction of this activity. A Catalyst common features pharmacophore was also constructed from three molecules known to activate their own metabolism included in the 38 molecules of the initial CYP3A4 model. This demonstrated that activators of CYP3A4 possess multiple hydrophobic regions that might correspond with a region in the active site away from the metabolic site.

[1]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[2]  S. Ekins,et al.  Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.

[3]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[4]  L. Benet,et al.  Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[5]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[6]  D. Greenblatt,et al.  Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N‐Desmethyladinazolam in Man , 1998, The Journal of pharmacy and pharmacology.

[7]  J. Liu,et al.  Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.

[8]  J. Robert,et al.  Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.

[9]  D. Lewis,et al.  Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.

[10]  L. Bertilsson,et al.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.

[11]  H. Kubinyi QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .

[12]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[13]  F. Guengerich,et al.  Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5. , 1997, Archives of biochemistry and biophysics.

[14]  M. Clay,et al.  In vitro biotransformation and identification of human cytochrome P450 isozyme-dependent metabolism of tazofelone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[16]  Barry C. Jones,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .

[17]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[18]  L. Benet,et al.  Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[19]  D. Lewis,et al.  In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. , 1997, Biochemical pharmacology.

[20]  G. Nelsestuen,et al.  Steady state enzyme velocities that are independent of [enzyme]: an important behavior in many membrane and particle-bound states. , 1997, Biochemistry.

[21]  J. Halpert,et al.  Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. , 1997, Biochemistry.

[22]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[23]  T. Koudriakova,et al.  Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents , 1997, Clinical pharmacology and therapeutics.

[24]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[25]  A. D. Rodrigues,et al.  Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[26]  F. Berthou,et al.  Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. , 1997, Life sciences.

[27]  A. Y. Lu,et al.  Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[28]  James R. Halpert,et al.  Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.

[29]  A. P. Koley,et al.  Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.

[30]  P. Souček,et al.  Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. , 1997, Biochemical pharmacology.

[31]  Roberto Todeschini,et al.  MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids , 1997, J. Comput. Aided Mol. Des..

[32]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[34]  L. Benet,et al.  Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. , 1996, Biochemical pharmacology.

[35]  J. Lasker,et al.  Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[36]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[37]  D. Lewis,et al.  Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[38]  L. Wienkers,et al.  Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[39]  B. K. Park,et al.  Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.

[40]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[41]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[42]  P. Maurel,et al.  Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.

[43]  S. Binkley,et al.  Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.

[44]  D. Greenblatt,et al.  Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. , 1996, Pharmacology.

[45]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[46]  M H Tarbit,et al.  Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[47]  A. D. Rodrigues,et al.  Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[48]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[49]  A. D. Rodrigues,et al.  In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[50]  D. Lewis Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[51]  A. P. Koley,et al.  CO Binding Kinetics of Human Cytochrome P450 3A4 , 1995, The Journal of Biological Chemistry.

[52]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[53]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[54]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[55]  S. Wrighton,et al.  In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[56]  T. Walle,et al.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. , 1994, The Journal of pharmacology and experimental therapeutics.

[57]  H. Yamazaki,et al.  Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. , 1994, Biochemical pharmacology.

[58]  R. Branch,et al.  Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[59]  S. M. Abel,et al.  Cortisol metabolism in vitro—III. Inhibition of microsomal 6β—hydroxylase and cytosolic 4-ene-reductase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[60]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[61]  X. J. Zhou,et al.  Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.

[62]  F. Guengerich,et al.  Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. , 1993, Drug Metabolism And Disposition.

[63]  X. J. Zhou,et al.  Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.

[64]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[65]  F. Gonzalez,et al.  Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. , 1992, Cancer research.

[66]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[67]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[68]  M. Eichelbaum,et al.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.

[69]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[70]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[71]  C. Miranda,et al.  Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver. , 1991, Carcinogenesis.

[72]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[73]  György G. Ferenczy,et al.  The active site of cytochrome P-450 nifedipine oxidase: a model-building study. , 1989, Journal of molecular graphics.

[74]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[75]  I Skånberg,et al.  In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.

[76]  F. Guengerich,et al.  Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.

[77]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.